Chinese biotech BeiGene (Nasdaq: BGNE) has started a trial that could signal the suitability of its immune checkpoint inhibitor tislelizumab – in combination with chemotherapy – for a massive patient group.
The first patient has been dosed in a Phase III trial of this combination to check its suitability as a potential first-line treatment in Chinese patients with stage three or four non-squamous non-small cell lung cancer (NSCLC).
In the trial, tislelizumab is being added to platinum plus pemetrexed chemotherapy, the current global standard of care in first-line treatment of patients with advanced stage non-squamous NSCLC.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze